Skip to content Skip to footer
Subscribe Now
Key Biosimilars Events of January 2025
INSIGHTS+

Key Biosimilars Events of January 2025

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        A major highlight was the Samsung Bioepis & Teva Partners to Commercialize Epysqli in…
February 4, 2025

Read more

Viewpoints_Dale Curtis Jr
VIEWPOINTS

Intelligent Automation and Beyond: Dale Curtis Jr from Astrix in an Enlightening Conversation with PharmaShots

Shots:  The biopharma industry faces several challenges, including digital transformation, regulatory compliance, and managing large volumes of data  Intelligent automation plays a vital role in drug discovery, clinical trials, manufacturing, and commercialization, helping optimize operations and better meet customer needs  Astrix CEO Dale Curtis Jr. discusses the role of AI and machine learning in global…
January 31, 2025

Read more

ThoughtSpot_Saurabh Chaubey
THOUGHTSPOT

Competitive Intelligence: A Substantial Advantage for the Pharmaceutical Sector

“The supreme art of war is to subdue the enemy without fighting” – Sun Zhu, Competitive Intelligence benefits your organization gather and analyzing information related to your competitor’s business models. This deep analysis helps your organization reduce the strategic risks and increase revenue opportunities by attaining deep insights into how the market has changed and…
October 11, 2022

Read more

PharmaShots Interview Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis
VIEWPOINTS

PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis

In an interview with PharmaShots, Jonathan Wang, Executive Vice President and Head of Business Development at Zai Lab shares his views on the license agreement with Karuna Therapeutics for KarXT (xanomeline-trospium) to treat schizophrenia and psychosis Shots: The companies collaborate to develop, manufacture & commercialize KarXT in Greater China including mainland China, Hong Kong, Macau & Taiwan Zai Lab gets exclusive rights to develop &…
February 28, 2022

Read more